Randomized Phase III Trial Results of Panitumumab, a Fully Human Anti—Epidermal Growth Factor Receptor Monoclonal Antibody, in Metastatic Colorectal Cancer
- 1 May 2006
- journal article
- research article
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 6 (1) , 29-31
- https://doi.org/10.3816/ccc.2006.n.01
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Safety, Pharmacokinetics, and Activity of ABX-EGF, a Fully Human Anti–Epidermal Growth Factor Receptor Monoclonal Antibody in Patients With Metastatic Renal Cell CancerJournal of Clinical Oncology, 2004
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapyCritical Reviews in Oncology/Hematology, 2001